Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

ArriVent BioPharma, Inc. (AVBP) Balance Sheet

As of 2026-06-30 (10-Q), ArriVent BioPharma, Inc. (AVBP) reported total assets of $394.7M, total liabilities of $27.9M and shareholders' equity of $366.8M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $154.7M.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

AVBPArriVent BioPharma, Inc.Follow AVBP — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
1.0B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
18 Nov, in 25 days
LineFY2024
Dec 24
FY2025
Dec 25
Latest
Jun 26
Trend
Cash and equivalents74.345.5154.7
Short-term investments144.6267.3218.4
Current assets227.0332.9394.2
Total assets274.9333.2394.7
Current liabilities17.325.927.8
Total liabilities17.325.927.9
Shareholders' equity257.7307.2366.8

USD millions · SEC XBRL

ArriVent BioPharma, Inc. — questions

How much cash does ArriVent BioPharma, Inc. have?
$154.7M in cash and cash equivalents as of 2026-06-30.
What are ArriVent BioPharma, Inc.'s total assets?
$394.7M as of 2026-06-30.
What is ArriVent BioPharma, Inc.'s shareholders' equity?
$366.8M as of 2026-06-30.

Every figure on this page comes from ArriVent BioPharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.